

FIRST-MOVER ADVANTAGE WITH COMPREHENSIVE WHOLE-GENOME SEQUENCING SCREENING TEST FOR

COMPANY OVERVIEW

GenEmbryomics is the first company in the world to offer a comprehensive whole-genome sequencing screening test for in vitro fertilization (IVF) embryos, providing a novel way to screen for genetic diseases before pregnancy. De novo mutations spontaneously occurring at fertilization account for over 4,525 genetic diseases that are routinely missed by currently used preimplantation genetic testing.

(PRIVATE)


GenEmbryomics, Pty. Ltd. HQ: Melbourne, Australia Leadership Team

Founder & CEO: Nick Murphy, PhD

COO: David Miyaoka CCO: Monica Petica, MSc

CTO: Kyle Day

Director: Santiago Munné PhD





VALUE PROPOSITION

GenEmbryomics has developed the world's first genetic screening for IVF capable of screening for more than 4,500 genetic conditions. GenEmbryomics innovative screening solution is comparatively priced to current testing solutions which have limited screening capabilities.

The Company is employing a B2B business model targeting IVF clinics globally. Initial commercialization plans are focused on the US, Europe, and Middle East, leveraging the key opinion leader status of the Company's Executive Director and Senior Advisor, Dr. Santiago Munné. Dr. Munné developed the first Preimplantation Genetic Diagnosis (PGD) test to detect embryonic numerical chromosome abnormalities to avoid Down's syndrome and other abnormalities and is extremely well-known amongst clinic owners.

Globally, the IVF market was estimated at \$16.9 billion in 2018 and is expected to grow to \$36.4 billion in 2026, a compound annual growth rate of 10.1%. GenEmbryomics is ideally positioned to capitalize on this demand, creating a compelling opportunity for early investors.









RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or opinions of the issues mentioned on this website at any time. The information contained herein is not intended to be used he basis for investment decisions and should not be construed as adviced investment the particular investment needs of any investor. The information or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness of the information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information; provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information provided on any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information.) Stock market investing is interesting si



GENOMESCREEN® VS. COMPETITORS

	Gen Embryomics	(g)enomic prediction	CooperSurgical*	natera [.]	lgenomix [,]	ORCHID
4,525 genetic diseases/test	✓	×	×	×	×	×
Single mutations	~	×	×	×	×	×
Chromosome number aneuploidy	✓	✓	✓	✓	✓	✓

INVESTMENT HIGHLIGHTS

Novel solutions addressing a multibillion-dollar market opportunity

- Developed world's first genetic screening for IVF capable of screening 4,500+ genetic conditions
- Global IVF market estimated at \$16.9 billion in 2018 and expected to surpass \$36 billion by 2026
- 300,000 IVF cycles performed in US annually

Near-term commercialization

- B2B model targeting IVF clinics
- Class II medical device with no clinical or pre-clinical studies required
- 10 LOIs/MOUs signed in US
- Excellent reimbursement potential

Substantial Intellectual Property

- 60+ patents & applications across 14 families
- 50+ granted patents globally, including US and Japan (70% of global market) and China (fastest growing market globally)

Highly experienced executive team

- Nick Murphy, PhD CEO/Founder: Co-inventor of the COVID-19 Risk test and Polygenic Risk Multi-Test (Genetic Technologies). First to directly sequence the human HLA system from a single chromosome.
- Santiago Munné, PhD Executive Director & Senior Advisor: PhD in Human Genetics (University of Pittsburgh). CIO at Overture Life. Founder of: Reprogenetics, Recombine, Phosphorus, MedAnswers, Overture Life, G1 Sciences. Advisory Board (currently): Overture Life, Phosphorus, MedAnswers, Butterfly & Sama
- Monica Petica, MSC Chief Clinical Officer: Monash IVF, Victorian Clinical Genetics Services (VCGS), Australian Forensic Police Services (Victoria, South Australia, Northern Territory)